Kaigene Inc., a biotechnology company pioneering next-generation antibody therapeutics for autoimmune disorders, has entered into an exclusive global licensing agreement with Celltrion Inc., a global biopharmaceutical company, for two of Kaigene’s nonclinical-stage assets, KG006 and KG002. KG006 is a next-generation FcRn inhibitor with a novel antibody structure, offering extended durability and best-in-class potential compared with existing therapies. KG002 is a first-in-class, dual-ac...